Kou Leon, Agarwal Sanjay, Miceli Alyssa, Kolb Logan, Krishnamurthy Karthik, Schmieder Shawn
St. Petersburg General Hospital, St. Petersburg, FL.
Department of Dermatology, Beaumont Trenton Hospital, Trenton, MI.
HCA Healthc J Med. 2021 Dec 29;2(6):397-400. doi: 10.36518/2689-0216.1198. eCollection 2021.
Programmed cell death receptor 1 (PD-1) inhibitors are promising and effective treatments for various cancers. Cutaneous adverse events, such as lichenoid drug eruptions, are well-known common side effects associated with PD-1 inhibitors. Lichenoid drug eruptions associated with PD-1 inhibitors show rapid improvement with high potency topical steroids and do not require cessation of the offending drug. We present the case of an 84-year-old female with progressive pembrolizumab therapy-associated lichenoid eruption that was resistant to several treatments and ultimately required discontinuation of pembrolizumab and treatment with methotrexate to resolve. This report includes histological findings of the pembrolizumab-associated lichenoid eruption.
程序性细胞死亡受体1（PD-1）抑制剂是治疗多种癌症的有前景且有效的疗法。皮肤不良事件，如苔藓样药疹，是与PD-1抑制剂相关的众所周知的常见副作用。与PD-1抑制剂相关的苔藓样药疹使用高效外用类固醇可迅速改善，且无需停用引起问题的药物。我们报告了一例84岁女性患者，其患有与帕博利珠单抗治疗相关的进行性苔藓样皮疹，对多种治疗均耐药，最终需要停用帕博利珠单抗并使用甲氨蝶呤治疗才能缓解。本报告包括帕博利珠单抗相关苔藓样皮疹的组织学检查结果。
